Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Equity (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Return on Equity for 9 consecutive years, with 1.29% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 99.0% to 1.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.29%, a 99.0% decrease, with the full-year FY2024 number at 0.85%, down 57.0% from a year prior.
  • Return on Equity was 1.29% for Q3 2025 at Rein Therapeutics, down from 1.25% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.19% in Q1 2024 to a low of 1.46% in Q1 2023.
  • A 5-year average of 0.82% and a median of 0.87% in 2024 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: surged 168bps in 2021, then crashed -103bps in 2025.
  • Rein Therapeutics' Return on Equity stood at 0.56% in 2021, then plummeted by -135bps to 1.33% in 2022, then skyrocketed by 78bps to 0.29% in 2023, then crashed by -199bps to 0.87% in 2024, then crashed by -48bps to 1.29% in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Return on Equity are 1.29% (Q3 2025), 1.25% (Q2 2025), and 1.22% (Q1 2025).